Protagenic Therapeutics resolves Nasdaq audit committee compliance issue, appoints Joshua Silverman

Protagenic Therapeutics, Inc.new

Nasdaq notified the Company of audit committee composition non-compliance from April 27 to September 30, 2021.
Dr. Jennifer Buell resigned from the Audit Committee; Joshua Silverman appointed effective October 1, 2021.
With Silverman's appointment, the Company is now in compliance with Nasdaq Listing Rule 5605(c)(2)(A).
It was later determined that Dr. Buell met independence requirements; she remains an independent board member.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.